ClinicalTrials.gg
RecruitingNCT06593639HNCANCERFITUpdated Nov 13, 2026

Effect of Prehabilitation on Head and Neck Cancer Patients

An interventional study of Prehabilitation before surgery and Prehabilitation before and during CRT in Head and Neck Cancer, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 13, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Head and Neck Neoplasms with a site in Italy — 42 open to participants now, 56 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.

Planned enrollment
74th of 97
60 · median 160
Started
2024
with 10 others
No phase
20 of 134
9 open now
Primary completion
2027-02
later than 29 of 55 live
Registered
110th of 134
by date

Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 74th largest by planned enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2024, is one of 20 with no phase, reaches primary completion later than 29 of the 55 other live ones, and was the 110th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

42 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Head and Neck Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The primary aim of the study is to investigate the feasibility of a prehabilitation program, which consists of a set of strategies including physical activity, nutritional support, and psychological counseling, carried out before and during cancer treatment for patients affected by head and neck tumors. About 4 weeks before surgery or the start of curative chemo-radiotherapy, the patient will begin the prehabilitation program, which will continue in parallel throughout the duration of the treatment and for up to 2 weeks after its completion. This prehabilitation program will include a combination of physical activity exercises, nutritional counseling, and psychological counseling sessions, all of which will be individualized for each patient. At the time of tumor diagnosis (T0), after 4 weeks of prehabilitation and before the start of the planned treatment (T1), 2 weeks after the end of treatment (T2), and after 6 months (T3), the patient will undergo a medical visit to collect anthropometric data, vital signs, a 6-minute walk test, and will complete a series of questionnaires aimed at assessing the risk of malnutrition, the development of anxiety and depression, and questionnaires to evaluate their quality of life. Throughout the duration of the study (i.e., up to T3, 6 months after the end of cancer treatment), the patient will wear an electronic watch, provided by the study, designed to measure vital signs, the number of daily steps, and the type and minutes of physical activity.

Read the detailed description

Oncological prehabilitation is defined as the process within the care pathway that takes place between the moment of cancer diagnosis and the initiation of acute treatments. Prehabilitation aims to improve physical, emotional, and cognitive health before the start of cancer therapy, with the ultimate goal of preventing and reducing treatment-related comorbidities and mortality. It has also proven effective in reducing the adverse events of cancer therapies during the active phase of treatment, making it potentially useful at any stage of the care pathway for cancer patients. The role of exercise, nutrition, and stress reduction in improving outcomes for cancer patients has long been recognized in surgical prehabilitation, but the evidence for benefits in non-surgical cancer treatments is weaker due to fewer randomized clinical trials. Improvements in muscle strength, a reduction in cancer-related comorbidities (e.g., dyspnea, cardiotoxicity, urinary incontinence), and a positive impact on quality of life, including social well-being and a reduction in anxiety, depression, and stress, have been demonstrated. However, the literature regarding the role of multimodal prehabilitation in head and neck cancers is even weaker: there is limited data on feasibility and effectiveness, with most studies focusing on optimizing nutritional status in malnourished patients or improving dysphagia, but lacking data from prospective clinical trials. This study is designed as a prospective, multicenter, experimental, non-randomized, uncontrolled interventional trial. The objectives are: i) to evaluate the feasibility of prehabilitation before and during curative treatment for patients with head and neck cancer; ii) to investigate the efficacy outcomes of prehabilitation; iii) to conduct a cost-effectiveness analysis of prehabilitation.

Feasibility will be assessed by measuring patient acceptance, adherence, and satisfaction with the program. To evaluate adherence to the physical activity intervention, patients will be provided with wearable devices capable of measuring daily steps, type, and minutes of activity. To evaluate adherence to nutritional support, subjects will be asked to complete a food diary along with telephone interviews conducted by expert professionals. Adherence to psychological support requires a combination of self-reported measures, clinical evaluation, and behavioral observation. A patient will be considered adherent if they complete at least 80% of the assigned tasks. The investigators will consider prehabilitation feasible if more than 50% of patients in the treatment group adhere to the program for the entire scheduled period. To investigate the efficacy of the treatment, validated questionnaires on quality of life and the patient's health status will be administered. Secondary endpoints will include the difference between questionnaire scores at the end versus the beginning of the intervention in terms of variables quantifying the response to cancer treatments and the patient's physiological status. It will also be possible to calculate both the cost-effectiveness and cost-utility balance of the intervention, considering the difference between the intervention arm and the historical control arm in terms of quality-adjusted life years. The activities carried out to achieve this objective will allow us to characterize the changes between the start and end of the intervention. Any significant (positive or negative) variation between the start and end of the intervention will be considered a result.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • head and neck cancer
  • prehabilitation
  • physical exercise
  • malnutrition
  • nutritional intervention
  • psychological support
  • cisplatin
  • hadrontherapy
  • ENT surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Candidate to curative treatment (platinum-based chemoradiotherapy or surgery + RT +/- CT)
  • PS 0-1
  • Fit for prehabilitation program (medical, physical, and mental conditions that don't contraindicate physical exercise and oral nutrition)
  • Ability to understand and adhere to exercise or lifestyle modifications
  • Date of treatment beginning no later than 60 days from baseline assessment
  • Provide valid prior to any study procedure

Exclusion criteria

Exclusion Criteria:

  • Unstable medical condition requiring immediate attention (e.g uncontrolled heart failure; unstable angina; severe respiratory distress) must prioritize
  • Patients with very advanced stage of disease, candidate to palliative treatment
  • Uncontrolled cancer symptoms or pain
  • Need for early treatment initiation
  • Frailty subjects: patients with severe functional impairment
  • Significant muscle wasting, limiting the participation in prehabilitation exercise
  • Severe cognitive or mental health issues, precluding prehabilitation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Surgery plus (chemo)radiotherapy

    Head and neck cancer patients undergoing surgery before (chemo)radiotherapy according to stage and risk factors.

    Other: Prehabilitation before surgery

  • Experimental
    Chemo-radiotherapy

    Head and neck cancer patients undergoing definitive concomitant chemo-radiotherapy (CRT) according to stage and risk factors.

    Other: Prehabilitation before and during CRT

Interventions

  • OtherPrehabilitation before surgery

    Prehabilitation multimodal program will start about 4 weeks before the surgery and will be continued until 2 weeks after the surgical intervention. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.

    Also known as: physical exercise, nutritional intervention, psychological support

  • OtherPrehabilitation before and during CRT

    Prehabilitation multimodal program will start about 4 weeks CRT and will be continued in parallel until 2 weeks after the end. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.

06

What researchers measure

Primary outcomes

  1. Feasibility of multimodal prehabilitation

    The feasibility will be measured by the rate of adherence to prehabilitation interventions. To assess the adherence to the physical activity intervention, the investigators will equip patients with commercially available activity trackers. Patients will wear the activity tracker until 6 months after the end of treatment. To assess the adherence to the nutritional intervention a telephone 24-hour dietary recall (24HR) interview will be employed. 24HR is a retrospective method that monitors and assesses the food and drinks consumption of the subjects during the previous day. Adherence to psycho-oncological support requires a combination of self-report measure, clinical assessment and behavioral observation. The three reports will be aggregated to a one reported value: a patient will be considered adherent to prehabilitation program if they will be adherent to each intervention.

    Time frame: From enrollment to the end of prehabilitation program, 2 weeks after the end of curative treatment

  2. Efficacy of multimodal prehabilitation

    A comparison between T0 (cancer diagnosis) and the other time points (T1: after 4 weeks of prehabilitation, T2: 2 weeks after the end of oncological treatments, T3: at 6 months of follow-up) will be made to exploit any differences. To test the efficacy of physical activity, the functional capacity over time will be monitored, measuring as the difference in absolute change in 6-minute walk distance (6MWD) between T0 and T1 and between T0 and T2. In addition, the Handgrip strength (HGS) will be employed as a biomarker of overall health status. Two questionaries (i.e. NRS-2002 and MUST) will be used as screening tools to exploit the risk of malnourishment. ASonA, Distress Thermometer, and FACT- HN will be used to test the psycho-oncological intervention efficacy. The three reports will be aggregated to a one reported value: the program will be considered effective if each intervention will be effective.

    Time frame: From enrollment to 2 weeks after the end of oncological treatment

  3. Cost-effectiveness of multimodal prehabilitation

    To evaluate the sustainability, the cost-utility analysis of the prehabilitation intervention will be evaluated. Cost Utility Analysis is an economic analysis comparing the incremental cost of a program to the incremental health improvement in terms of quality adjusted life years (QALYs). The EORTC QLQ-C30 questionnaire will be used to predict EQ-5D-5L through a mapping algorithm, which is one of the most used instrument for measuring QALYs.

    Time frame: From the enrollment to 6 months after the end of the oncological treatment

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Cantwell LA, Fahy E, Walters ER, Patterson JM. Nutritional prehabilitation in head and neck cancer: a systematic review. Support Care Cancer. 2022 Nov;30(11):8831-8843. doi: 10.1007/s00520-022-07239-4. Epub 2022 Aug 1. PubMed 35913625 ↗
  • Loughney L, West MA, Moyses H, Bates A, Kemp GJ, Hawkins L, Varkonyi-Sepp J, Burke S, Barben CP, Calverley PM, Cox T, Palmer DH, Mythen MG, Grocott MPW, Jack S; Fit4Surgery group. The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients: a randomised controlled trial (The EMPOWER Trial). Perioper Med (Lond). 2021 Jun 22;10(1):23. doi: 10.1186/s13741-021-00190-8. PubMed 34154675 ↗
  • Urvaylioglu AE, Kutluturkan S, Kilic D. Effect of Kegel exercises on the prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy. Eur J Oncol Nurs. 2021 Apr;51:101913. doi: 10.1016/j.ejon.2021.101913. Epub 2021 Feb 15. PubMed 33639454 ↗
  • Halkett G, O'Connor M, Jefford M, Aranda S, Merchant S, Spry N, Kane R, Shaw T, Youens D, Moorin R, Schofield P; RT Prepare project team. RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy. Br J Cancer. 2018 Jun;118(12):1549-1558. doi: 10.1038/s41416-018-0112-z. Epub 2018 Jun 1. PubMed 29855611 ↗
  • Goldsmith I, Chesterfield-Thomas G, Toghill H. Pre-treatment optimization with pulmonary rehabilitation in lung cancer: Making the inoperable patients operable. EClinicalMedicine. 2020 Nov 30;31:100663. doi: 10.1016/j.eclinm.2020.100663. eCollection 2021 Jan. PubMed 33554075 ↗
  • Quist M, Langer SW, Lillelund C, Winther L, Laursen JH, Christensen KB, Rorth M, Adamsen L. Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial. Lung Cancer. 2020 Jul;145:76-82. doi: 10.1016/j.lungcan.2020.05.003. Epub 2020 May 8. PubMed 32416432 ↗
  • Lippi L, Turco A, Moalli S, Gallo M, Curci C, Maconi A, de Sire A, Invernizzi M. Role of Prehabilitation and Rehabilitation on Functional Recovery and Quality of Life in Thyroid Cancer Patients: A Comprehensive Review. Cancers (Basel). 2023 Sep 10;15(18):4502. doi: 10.3390/cancers15184502. PubMed 37760472 ↗
  • Howe L, Husband A, Robinson-Barella A. Prescribing pre- and post-operative physical activity interventions for people undergoing breast cancer surgery: A qualitative systematic review. Cancer Med. 2024 Feb;13(4):e7063. doi: 10.1002/cam4.7063. PubMed 38457236 ↗
  • Voorn MJJ, Driessen EJM, Reinders RJEF, van Kampen-van den Boogaart VEM, Bongers BC, Janssen-Heijnen MLG. Effects of exercise prehabilitation and/or rehabilitation on health-related quality of life and fatigue in patients with non-small cell lung cancer undergoing surgery: A systematic review. Eur J Surg Oncol. 2023 Oct;49(10):106909. doi: 10.1016/j.ejso.2023.04.008. Epub 2023 May 2. PubMed 37301638 ↗
  • Waterland JL, McCourt O, Edbrooke L, Granger CL, Ismail H, Riedel B, Denehy L. Efficacy of Prehabilitation Including Exercise on Postoperative Outcomes Following Abdominal Cancer Surgery: A Systematic Review and Meta-Analysis. Front Surg. 2021 Mar 19;8:628848. doi: 10.3389/fsurg.2021.628848. eCollection 2021. PubMed 33816546 ↗
  • Sabajo CR, Ten Cate DWG, Heijmans MHM, Koot CTG, van Leeuwen LVL, Slooter GD. Prehabilitation in colorectal cancer surgery improves outcome and reduces hospital costs. Eur J Surg Oncol. 2024 Jan;50(1):107302. doi: 10.1016/j.ejso.2023.107302. Epub 2023 Nov 28. PubMed 38043359 ↗
  • Molenaar CJL, Minnella EM, Coca-Martinez M, Ten Cate DWG, Regis M, Awasthi R, Martinez-Palli G, Lopez-Baamonde M, Sebio-Garcia R, Feo CV, van Rooijen SJ, Schreinemakers JMJ, Bojesen RD, Gogenur I, van den Heuvel ER, Carli F, Slooter GD; PREHAB Study Group. Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial. JAMA Surg. 2023 Jun 1;158(6):572-581. doi: 10.1001/jamasurg.2023.0198. PubMed 36988937 ↗
  • Barberan-Garcia A, Ubre M, Roca J, Lacy AM, Burgos F, Risco R, Momblan D, Balust J, Blanco I, Martinez-Palli G. Personalised Prehabilitation in High-risk Patients Undergoing Elective Major Abdominal Surgery: A Randomized Blinded Controlled Trial. Ann Surg. 2018 Jan;267(1):50-56. doi: 10.1097/SLA.0000000000002293. PubMed 28489682 ↗
  • Silver JK, Flores LE. Integrating Prehabilitation into the Cancer Survivorship Framework. Eur Urol Focus. 2024 Jan;10(1):23-25. doi: 10.1016/j.euf.2023.11.006. Epub 2023 Nov 22. PubMed 37996272 ↗
  • Carli F, Silver JK, Feldman LS, McKee A, Gilman S, Gillis C, Scheede-Bergdahl C, Gamsa A, Stout N, Hirsch B. Surgical Prehabilitation in Patients with Cancer: State-of-the-Science and Recommendations for Future Research from a Panel of Subject Matter Experts. Phys Med Rehabil Clin N Am. 2017 Feb;28(1):49-64. doi: 10.1016/j.pmr.2016.09.002. PubMed 27913000 ↗
  • Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, Irwin ML, Late M, Mansfield S, Marshall TF, Meyerhardt JA, Thomson CA, Wood WA, Alfano CM. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-2507. doi: 10.1200/JCO.22.00687. Epub 2022 May 16. PubMed 35576506 ↗
  • Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil. 2013 Aug;92(8):715-27. doi: 10.1097/PHM.0b013e31829b4afe. PubMed 23756434 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Feb 2027, 29 months after the start.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 29 months is below that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Aug 2026 → Feb 2027 and completion Aug 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Sep 9, 2024
Primary completionEst.
Feb 2027was Aug 2026
CompletionEst.
Feb 2027was Aug 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (5 Italy)
  • Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale · Naples, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Istituti Clinici Scientifici Maugeri · Pavia, Italy
  • National Center of Adrotherapy Oncology · Pavia, Italy
  • Azienda Ospedaliero Universitaria di Sassari · Sassari, Italy
Show 5 removed
  • Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale · Naples, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Istituti Clinici Scientifici Maugeri · Pavia, Italy
  • National Center of Adrotherapy Oncology · Pavia, Italy
  • Azienda Ospedaliero Universitaria di Sassari · Sassari, Italy
Nov 13, 2026
Primary completion
Aug 2026→Feb 2027
Nov 13, 2026
Study completion
Aug 2026→Feb 2027
Nov 13, 2026
Sponsor
Laura Deborah Locati→Istituti Clinici Scientifici Maugeri SpA
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    5 sites added, 5 sites removed
    Show 5 added (5 Italy)
    • Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale · Naples, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Istituti Clinici Scientifici Maugeri · Pavia, Italy
    • National Center of Adrotherapy Oncology · Pavia, Italy
    • Azienda Ospedaliero Universitaria di Sassari · Sassari, Italy
    Show 5 removed
    • Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale · Naples, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Istituti Clinici Scientifici Maugeri · Pavia, Italy
    • National Center of Adrotherapy Oncology · Pavia, Italy
    • Azienda Ospedaliero Universitaria di Sassari · Sassari, Italy
    Primary completion Aug 2026→Feb 2027
    Study completion Aug 2026→Feb 2027
    Sponsor Laura Deborah Locati→Istituti Clinici Scientifici Maugeri SpA
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06593639
Collaborators
Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliero Universitaria di Sassari, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 9, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Laura D Locati, MD, PhD
Contact
oncologiapavia@icsmaugeri.it
+39 0382593585

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion